ADMA Biologics - Earnings Call - Q2 2025

Executive Summary

• ADMA delivered Q2 2025 revenue of $122.0M (+14% YoY, +29% underlying ex-2024 Medicaid rebate reversal) and GAAP diluted EPS of $0.14, modestly above S&P Global consensus on both revenue and EPS; gross margin expanded to 55.1% from 53.6% YoY. Results vs consensus in “Estimates Context” (S&P Global).
• Management reaffirmed FY25–FY26 guidance (FY25 revenue ≥$500M; Adj. EBITDA ≥$235M; Adj. Net Income ≥$175M; FY26 revenue ≥$625M; Adj. EBITDA ≥$340M; Adj. Net Income ≥$245M), noting 2025 guidance excludes upside from the FDA‑approved yield enhancement process and that benefits are conservatively reflected in 2026.
• Commercial-scale manufacturing with the FDA-approved yield enhancement is underway; initial batches are delivering >20% higher finished IG output, expected to drive gross margin expansion as yield-enhanced lots begin monetization late 2025 and more fully in 2026.
• Strategic catalysts: J.P. Morgan–led $300M debt refinancing (lower borrowing costs, added $225M revolver), $15M share repurchases in Q2, and acquisition of an adjacent Boca Raton site enabling up to 30% future cGMP capacity expansion; ASCENIV utilization hit record highs, underpinning H2 acceleration and FY outlook.

What Went Well and What Went Wrong

• What Went Well

  • Yield enhancement manufacturing began; initial commercial batches delivered the anticipated >20% IG output increase, a key margin inflection driver starting late 2025/2026.
  • ASCENIV demand continued to reach record highs, supporting rising mix of higher-margin IG and underpinning H2 growth acceleration.
  • Capital structure and liquidity improved via $300M syndicated refinancing (ABR +150–200 bps / SOFR +250–300 bps spreads; $225M revolver + $75M term loan), lowering average borrowing costs and adding flexibility; $15M of buybacks executed in Q2.

• What Went Wrong

  • Underlying YoY comparisons remain complicated by the prior-year $12.6M Medicaid rebate accrual reversal; management continues to present “underlying” growth to normalize the base.
  • Monetization timing of yield-enhanced lots cautious: 2025 guidance excludes yield benefits; management indicates more visible accretion in 2026, delaying full P&L capture of manufacturing gains.
  • Inventory built strategically by $19.3M to support ASCENIV growth; while intentional, the working capital step-up is a near-term cash use as the supply chain scales.

Transcript

Speaker 4

Good afternoon and welcome to the ADMA Biologics Second Quarter 2025 Financial Results and Business Update Conference Call on Wednesday, August 6th, 2025. At this time, all participants are in a listen-only mode. There will be a question-and-answer session to follow. Please be advised that this call is being recorded at the company's request and will be available on the company's website approximately two hours following the end of the call. At this time, I would like to introduce the company. Please go ahead.

Speaker 3

Welcome, everyone, and thank you for joining us this afternoon to discuss ADMA Biologics' financial results for the second quarter of 2025 and recent corporate updates. I'm joined today by Adam Grossman, President and Chief Executive Officer, Brad Tade, Chief Financial Officer and Treasurer. During today's call, Adam will provide some introductory comments and provide an update on corporate progress, and then Brad will provide an overview of the company's second quarter 2025 financial results. Finally, Adam will then provide some brief summary remarks before opening up the call for questions. Earlier today, we issued a press release detailing the second quarter 2025 financial results and summarized certain achievements in recent corporate updates. The release is available on our website at www.admabiologics.com.

Before we begin our formal comments, I'll remind you that we will be making forward-looking assertions during today's call that represent the company's intentions, expectations, or beliefs concerning future events, which constitute forward-looking statements for the purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to factors, risks, and uncertainties, such as those detailed in today's press release announcing this call and in our filings with the SEC, which may cause actual results to differ materially from the results expressed or implied by such statements. In addition, any forward-looking statements represent our views only as of the date of this call and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligations to update any such statements except as required by the Federal Securities Laws.

We refer you to the Disclosure Notice section in our earnings release we issued today, in the Risk Factors section in our SEC filings, and our quarterly report on Form 10-Q for the quarter ended June 30, 2025, for a discussion of important factors that could cause actual results to differ materially from these forward-looking statements. Please note that the discussion on today's call includes certain non-GAAP financial measures, including adjusted EBITDA and adjusted net income. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP metric is available in our earnings release. With that, I would now like to turn the call over to Adam Grossman. Adam, go ahead. Thank you, Skyler. Good afternoon, everyone. ADMA Biologics' second quarter 2025 performance underscores the strength of our operating model, the success of our strategic execution, and our unwavering commitment to innovation.

During the quarter, we advanced key growth initiatives, enhanced our supply chain infrastructure, and further solidified ADMA Biologics' leadership position in the specialty biologics market. We are pleased to report that commercial-scale production utilizing our FDA-approved yield enhancement process is now successfully underway. Initial production has achieved the expected 20% or greater increase in bulk Ig output, validating this proprietary manufacturing advancement. We expect this efficiency gain to drive meaningful gross margin expansion and improve production throughput beginning in early 2026, with continued benefits expected in the years ahead. On the commercial front, ASCENIV continues to gain momentum, with utilization reaching record highs in the second quarter. With expanded availability of high titer plasma and strong forward demand indicators, we believe we are well positioned to deepen market penetration and broaden patient access.

Medical community feedback remains positive, and the recent acceleration in new patient starts further highlights ASCENIV's differentiated clinical value. Our financial results for the second quarter reflect substantial growth in operational achievements. Total revenues reached $122 million on a reported basis. On an underlying basis, excluding the non-recurring $12.6 million Medicaid rebate accrual reversal that benefited the second quarter of 2024, total revenue grew by approximately 29%. On the same underlying basis, second quarter 2025 adjusted net income and adjusted EBITDA grew approximately 85% and 59% year over year, respectively. We are confidently reaffirming all previously issued financial guidance, with growth rates anticipated to accelerate significantly in the second half of 2025 and beyond. These results underscore the efficacy of our biologic therapies for immunocompromised patients across the U.S., as well as the dedication and expertise of our leadership team and exceptional staff.

Importantly, this week we completed a JPMorgan-led debt refinancing, replacing our prior term loan and meaningfully reducing our borrowing costs. The new credit agreement, totaling $300 million, and comprised of a $75 million term loan to refinance the previously held debt with ARES, as well as a $225 million revolving credit facility, features leverage-based pricing tiers with revolving credit facility spreads ranging from 1.5% to 2% and term loan spreads from 2.5% to 3%. This refinancing, which is effective as of August 5, 2025, and therefore not yet reflected in the second quarter financial statements, is expected to lower ADMA Biologics' weighted average cost of debt, enhance liquidity, and provide additional financial flexibility to support our long-term strategic growth initiatives. Operationally, in July, we expanded our operating infrastructure with the acquisition of a facility and adjacent land near our Boca Raton campus.

This investment is expected to provide additional operating flexibility to support our growth trajectory through expanded cold storage, warehousing and inventory management, in-house testing, and potential new distribution opportunities, as well as could enable up to a 30% expansion of CGMP manufacturing space over time. Importantly, this acquisition further entrenches our fully U.S.-based supply chain and should enhance our scalability and resilience in alignment with rising demand for American-made healthcare solutions. We expect go-forward capital expenditures supporting this infrastructure expansion to remain modest and ultimately expected to deliver a highly compelling return on investment. In the second quarter, we also activated our authorized $500 million share repurchase program and repurchased approximately $15 million of ADMA Biologics common stock. Supported by strong free cash flow, we view these repurchases as a highly value-accretive use of capital and intend to remain opportunistic in future periods.

Including a proactive $19.3 million increase in inventories, primarily consisting of raw material to support accelerating ASCENIV production, we generated meaningfully positive free cash flow during the quarter, ending the period with $90.3 million in total cash. Internal and external plasma collection volumes reached new highs, positioning us well to support ongoing commercial expansion. These achievements reinforce our confidence in delivering on our long-term growth targets, including reaching $1.1 billion or more in annual revenue prior to 2030, while continuing to expand access to our differentiated Ig therapies. Beginning in the back half of 2025 and continuing on our pathway to this intermediate-term revenue target, we anticipate significant margin expansion on a go-forward basis. Our R&D pipeline continues to progress. We initiated studies in a first-of-its-kind animal model designed to evaluate S. pneumoniae infection in both normal and immunocompromised hosts.

In initial pilot testing, SG-001 treated animals exhibited no clinical signs of pneumonia 24 hours post-bacterial challenge, while placebo-treated animals developed observable symptoms. Establishing this model is expected to accelerate ADMA Biologics' preclinical research and development of SG-001. If successful, the product could represent a potential $300 to $500 million annual revenue opportunity, supported by strong gross margins and patent protection through at least 2037. Following the initial data readout, we expect to be in a position to rapidly advance SG-001 into clinical and registrational studies, leveraging our existing commercial platform to drive a potentially accelerated path to peak sales. Before turning over the call to Brad, I'd like to express my sincere appreciation to our exceptional team at ADMA Biologics. Your continued dedication, ingenuity, and mission-driven focus continue to power our momentum.

The progress we are reporting today is a direct reflection of your hard work and passion, and together we are shaping a stronger future for patients and the broader healthcare ecosystem. With that, I'll now hand it over to Brad to walk through our second quarter financials in more detail. Thank you, Adam. Earlier today, we issued a press release outlining our second quarter 2025 financial results. I'll now summarize key highlights from the quarter. Total revenue was $122 million, up 14% year over year, or approximately 29% when adjusting for the non-recurring $12.6 million Medicaid rebate accrual reversal that benefited the second quarter of 2024. This growth was driven primarily by continued strong adoption and utilization of ASCENIV across physicians, payers, and patients. Gross profit increased to $67.2 million, with gross margins improving to 55.1% from 53.6% a year ago.

Adjusted for the prior year Medicaid rebate accrual, underlying gross margin expanded by 7.7%, reflecting a favorable mix of higher margin Ig sales and improved manufacturing efficiencies. GAAP net income was $34.2 million, while adjusted net income increased to $36 million, representing an 85% underlying growth year over year when normalizing for the prior year Medicaid rebate accrual. Adjusted EBITDA grew to $50.8 million, up 59% on an underlying basis after adjusting for the Medicaid rebate accrual benefit. Including a strategic step-up in inventory of $19.3 million quarter over quarter to support ASCENIV demand, we delivered robust free cash flow, ending the quarter with $90.3 million in cash. Continued EBITDA growth and cash generation are expected to further strengthen our balance sheet in the second half of 2025, positioning ADMA Biologics to weather broader credit and equity market volatility.

Reflecting this financial strength, we repurchased approximately $15 million of common stock under our $500 million program during the second quarter. We continue to view buybacks as a value-enhancing capital allocation strategy, supported by our growth trajectory and our earnings outlook. As Adam mentioned, this week we executed a new $300 million senior-secured credit facility led by JPMorgan, consisting of a $75 million term loan drawn at closing to replace previously held debt, as well as an undrawn $225 million revolving credit facility. The facility features a three-year tenor and is secured by a blanket lien on all assets and stock, consistent with customary market terms. Pricing is based on total leverage with drawn spreads ranging from adjusted SOFR plus 250 basis points to 300 basis points, and commitment fees of 30 to 35 basis points.

We intend to utilize the revolving credit facility opportunistically, primarily to support share repurchases, working capital needs, and other general corporate purposes, while maintaining flexibility in our capital structure. Importantly, the refinancing replaces our prior indebtedness, lowers our overall cost of capital, and enhances liquidity to support long-term growth initiatives. These terms, combined with anticipated strong cash generation, provide ADMA Biologics with meaningful flexibility and capacity to execute on our strategy and priorities. Building on our strong year-to-date performance, we are reaffirming our previously provided financial guidance for both 2025 and 2026. For 2025, we continue to expect total revenue of $500 million or more, adjusted EBITDA of at least $235 million, and adjusted net income of $175 million or more.

This guidance does not include any potential accretion from the monetization of products sold using our now approved enhanced yield process, reflecting conservative assumptions regarding the timing of production ramp-up and lot releases. Looking ahead to 2026, we are reaffirming our financial outlook, underpinned by the recent FDA approval of our enhanced yield production process and continued commercial momentum. For 2026, we reaffirm our expectation of at least $625 million in total revenue, adjusted EBITDA of $340 million or more, and adjusted net income of at least $245 million. This outlook remains consistent with our historical financial targets and reflects anticipated margin expansion driven by our growing ASCENIV revenue mix. Additionally, we reaffirm our expectation that annual revenue prior to 2030 will exceed $1.1 billion, compared to our previously communicated expectation of $1 billion, with meaningful margin expansion expected over the same period.

Looking ahead, we believe we are well positioned to accelerate our revenue and earnings growth rates in the back half of 2025, grow free cash flow, and continue to reduce our weighted average cost of capital, all of which we are confidently executing on while concurrently advancing all our growth initiatives. With that, I'll turn the call back over to Adam for closing remarks. Thank you, Brad. ADMA Biologics is executing across all fronts, commercially, operationally, and strategically. The success of our yield enhancement production process, record ASCENIV utilization, debt refinancing, and infrastructure investments all provide clear visibility into anticipated sustained margin expansion and earnings growth in the immediate quarters ahead. As we scale toward both our near-term and long-range financial goals, our focus remains centered on operational excellence, disciplined capital allocation, and innovation that puts patients first.

We believe our fully U.S.-domestic vertically integrated model continues to provide us with unique supply chain control and long-term resilience. We remain unwavering in our mission to deliver high-quality, differentiated Ig therapies to those who need them most. Every investment we make, whether advancing SG-001, expanding U.S.-based operations, or strategically repurchasing shares, is guided by a long-term growth mindset focused on maximizing value for stockholders and patients alike. With strong stakeholder partnerships, a growing base of treated patients, and a passionate team driving us forward, we believe ADMA Biologics is uniquely situated to be one of the most durable and compelling growth stories in all of biopharma. We're proud of what we achieved and are energized for what lies ahead. With that, I'd now like to open up the call for questions. Thank you.

Speaker 4

Thank you. Today's question-and-answer session will be conducted electronically. We'll pause just a moment to assemble the roster. First question comes from the line of Rick Miller at Cantor Fitzgerald. Please go ahead. Your line is open.

Speaker 0

Hey, this is Rick on for Skyler Bloom. Hey, good. Thanks for taking the questions. I've got a couple here. You mentioned seeing record high ASCENIV utilization. Are you seeing any changes in trends in how physicians are deploying the specialized product and prioritizing different cases for ASCENIV?

Speaker 3

Thanks, Rick. We're seeing the same thing that we've been seeing throughout ASCENIV's growth period, and we're seeing it into the third quarter. We've defined appropriate use. Again, it's this refractory, highly comorbid PI patient that has been on Ig, and we're seeing new patient starts, patients switching off of standard Ig therapies, moving on to ASCENIV, and we're seeing the same trends continuing. Same store utilization looks great. We're adding new docs all the time. We've got more product coming off the line, and everything we said, Rick, is happening right now. All the guidance that we've provided previously is coming to fruition, and we're seeing really good utilization uptake in the market and expanding into new clinics. It's pretty much the same as it has been, and we expect it to continue to compound as we progress throughout the second half of this year and into 2026.

Speaker 0

Okay, hoping to ask a question also on the science behind yield enhancement. What does the actual process here for the FDA-approved yield enhancement process look like? Is your team basically working with different purification columns to sort of get back some of the IVIG that was previously lost? Anything to kind of help us understand what's going on sort of under the hood?

Speaker 3

Sure. You know, as we've explained previously, when you produce Ig, there are certain waste streams that are separated out of the final product. These waste streams contain some IgG. They also contain different aggregates and impurities that we want to remove. The team here at ADMA Biologics has developed a methodology where we can take one of the waste streams where we lose the largest portion of Ig in the manufacturing process, resuspend that paste, purify it, put it over some chromatography columns, some filtration steps, and then blend it back together with the original part of the process. What it's doing is it's taking something that was waste and really bringing it back into the downstream purification part of our process, and we are seeing the anticipated gains of 20% or more from every batch of product that we are producing.

We've been producing at this FDA-approved yield enhancement process scale since, I believe, it's the middle of May, and we're seeing great results as expected. Taking something that was trash and turning it into 20% more bulk Ig output, this is going to enhance gross margin expansion for our Ig portfolio, BIVIGAM, and ASCENIV, and ultimately provide more product to patients that still seem to be in an undersupply situation in a growing Ig market in the U.S.

Speaker 0

Great. Thank you, and I'll hop back in the queue.

Speaker 4

One moment for our next question.

Speaker 3

Thanks, Rick.

Speaker 4

Our next question comes from Anthony Petrone with Mizuho Group. Go ahead. Your line is open.

Speaker 2

Thanks, and good afternoon, everyone.

Speaker 3

Hey, Anthony.

Speaker 2

How are you, Adam? Maybe Adam and/or Brad want to just kind of go through moving parts on the reaffirmed guidance and the outlook through 2026. You are getting the record RSV collections from, I would assume, the external supply contracts signed earlier in the year. Yield enhancement is now here. You're not baking it in. Just curious the calculus there. It sounds like there's more visibility on the supply front. What is going to be the trigger to sort of seeing that come through to fruition in the guidance as we look into the second half of the year and the start of next year?

Speaker 3

Sure. I mean, I'll just start off by saying, Anthony, you know, our guidance was strong as we ended last year and entered this year. We're conservative as always. The approach that we take to guidance construction has not changed. We are aiming to beat the guidance that we currently have out there, but we feel really, really good about where we are from a raw material perspective. Manufacturing has been going extremely well, especially with yield enhancement now. We're seeing that step up in inventory valuation, and we're working expeditiously to work through all of the previous process-produced product that we would be selling at a lower margin and trying to accelerate to where we can realize revenue from the new FDA-approved yield enhancement process. It's not in 2025 guidance.

It's heavily risk-adjusted for 2026, and as we continue to progress, I mean, we do expect to see accelerating margin expansion and, obviously, top-line sales in the back half of this year, and that's the guidance that we've been given since January. Again, conservative approach. We always said the beginning part of 2025, you're going to see growth, but it's going to be modest growth, and where you're going to see that acceleration is in the back half of this year. We've been making more ASCENIV. We made more ASCENIV at the end of last year, beginning of this year, working down some of our inventories. Our third-party suppliers, as you mentioned, have been delivering really, really well for us. Really very, very pleased with the relationship between Grifols and Kedrion.

We're getting more plasma than we anticipated, and we feel really good about the inventory levels, and we're turning it into finished goods, and the finished goods are moving off the shelves. Everything is coming together as we planned.

Speaker 2

Exactly. You saw the strategic $19.3 million RSV investment, and obviously, we're doing that as we anticipate accelerated growth in the back half of 2025 and to support 2026 as well.

Speaker 0

No, that's helpful. A couple of follow-ups here. One would be on just kind of looking at how it's set now. If you take your first half and look at the second half of the year with the guidance unchanged, it's a little bit of a deceleration. You don't have FDA-approved yield enhancement in there or the benefit of supply, but I would assume you're not signaling any major change in sort of the demand picture in the back half of the year. The last one, if I could just sneak it in, can you give us just a high-level overview, Adam, of the cost-benefit analysis to hospitals specifically here with an ASCENIV patient? These patients are typically hospitalized for quite a bit. It does appear there's literature out there that you get a sooner discharge. I'm just wondering if there's any numbers you can put around that. Thanks again.

Speaker 3

This is Anthony. Can you repeat that part again? This is with respect to ASCENIV in the hospital?

Speaker 0

Yeah. First is on the guide, just again, you know, there's an implied decel in the second half. Just want to make sure that the demand picture is steady. Then just the cost-benefit of using ASCENIV. You're certainly getting the benefit with these patients. Just wondering when you compare that head-up to, you know, standard therapy, whether it's Ig or combination therapy, you know, how that stacks up.

Speaker 3

Sure.

Speaker 0

Thanks.

Speaker 3

Understood. First half of the year, total revenues are, I'm just doing the math, like $236 million. Back half of the year will be growing, at least, call it $265 million. There is growth that is going to, that is baked into our current guidance. Again, as I've said, we take a conservative approach, and we are expecting to beat, and the way it looks from my vantage point is we've got the inventory in work in process and coming off the line, and we should have more product to deliver to the market. As I stated with Rick's question, the demand indicators are still very, very strong.

We're still working through our health economics outcomes work, Anthony, so we'll have information on that hopefully later this year, but I can tell you from a clinical perspective, patients that are on standard Ig and that continue to suffer chronic and persistent infections costing the healthcare system money, taking up time at their physician's offices, in and out of the hospital, that are getting hospitalized for serious bacterial and viral infections. When these patients are switched from standard Ig to ASCENIV, they don't go to the hospital. They don't suffer from these chronic and persistent infections that they have been experiencing for sometimes years. The value proposition is still there.

You're taking these problematic patients that are causing tremendous problems for their treaters, for their families that are not living a normal quality of life, and we're giving them a renewed chance to live a productive and normal life while keeping them out of the hospital. From my view, remodeling, a reacceleration of growth starting in the third quarter, that's what our guidance outlook tends to.

Speaker 2

Yeah, Anthony, I would say it's similar to how Adam is saying it. Our guidance implies we are confidently reiterating a growth reacceleration in the third quarter and beyond, and we are preparing our supply chain and our manufacturing processes to meet and exceed that reaccelerated growth.

Speaker 0

Fair enough. Thank you. I'll get back in queue. Thanks.

Speaker 4

One moment for the next question. Next question comes from Gary Nachman with Raymond James. Please go ahead. Your line is open.

Speaker 1

Thanks, Adam. Good afternoon.

Speaker 0

You're good.

Speaker 1

Okay. First, Adam, you noted more physicians are using ASCENIV. Maybe talk about, you know, some of the initiatives that you have to expand physician use of ASCENIV. If it's currently about 100 physicians or so, that's a number you've said in the past, that are using it, and maybe the target group is about 300, you know, how do you bridge that gap? When can you be more aggressive promoting to the docs? Do you need to have the supply in a certain place before you do that? As they're putting new patients on, are they getting any pushback at all from the payers? Just give us an update also on the whole reimbursement situation.

Speaker 3

Sure. Gary, new docs are coming online all the time. From an aggressive standpoint, we've alleviated what we believe have been the bottlenecks in producing product. For the forward-looking periods, we believe that we've got product on the shelf ready to go to start these patients aggressively, and you're going to see that again beginning what we believe is this period in the third quarter throughout the back half of this year into 2026. Nothing is easy with payers, but in the appropriate use cases, we're seeing limited payer pushback. We do have to jump through hurdles like all Igs do. About 70% of Ig requires prior authorization, and we built out our teams from a field reimbursement perspective, and we're working hand in hand with these clinicians, providing them with data from the literature and helping them to alleviate any reimbursement hurdles that they may find.

Patients who should be on ASCENIV are getting onto the product. It may take a couple of weeks. It may take a couple of months, but ultimately, these patients, if their doctors are advocating for it, they're getting therapy. About half of our business for the immunoglobulin portfolio is through Medicare. The other half is through commercial payers. It's spread across 60 to 100 different commercial payers, so there isn't one payer bearing the burden. Things look very good. Medical education is really what triggers the light bulb in these patients, in these doctors' minds, targeting the Ig infusion nurses, the nurses that are dealing with the patients directly or their families.

We're seeing no decline in level of interest or excitement about the product, and certainly, the experiences that have been reported to me from new clinics and new clinicians in the field when they've started with ASCENIV have nothing but been positive feedback to me.

Speaker 1

Okay. On that point regarding medical education and what you just responded before to Anthony regarding the HEOR data, you said you should have that later this year. Can you put a little bit of a timeframe around that and what maybe we hope to see with that data and how important you think that might be going out to the physicians and the payers? Yeah, so they have a little bit more data and evidence about the benefit with ASCENIV.

Speaker 3

Sure. We're continuing to generate data all the time through investigator-initiated grants, studies, and investigations. A number of publications have been coming out, poster presentations at various conferences around. We are culling the database and looking at claims data. What I'm hoping to see is exactly what I've been explaining over the last couple of years, is that you're going to see a large clinical benefit when you take an appropriate-use patient who's been receiving Ig and is in and out of the hospital. When you put them on ASCENIV, you're keeping them out of the hospital. You're reducing all total healthcare expenditures. Obviously, we believe that the clinical outcomes for ASCENIV in this patient population are certainly going to be great data. Later this year is all I can tell you.

I'm not the statistician, and I'm not the one digging in there, but we will keep you and the street abreast of data as it comes available, and we'll make appropriate publications and presentations at medical conferences throughout the rest of this year and into next year.

Speaker 1

Okay, great. Just on the gross margins, which obviously are expected to improve, as we're thinking about the pace of this improvement, are there any headwinds maybe in terms of, I don't know, if just the cost of ensuring that you have appropriate plasma supply or rebates that you're offering your customers or things like that? Is there anything going in the other direction that might be holding back gross margin a little bit? I don't know if maybe you could bookend, so we have a sense of how to think about gross margin expansion this year and maybe the magnitude of how that could improve next year.

Speaker 2

Gary, right now we are not seeing any headwinds to gross margin. We have secured RSV plasma supply, which allows us to make the ASCENIV and products that we need. We will start monetizing yield-enhanced production batches, hopefully at the end of this year, certainly all of 2026. You'll continue to see margin accretion with yield enhancement and with Ig mixed shift. Right now we are not seeing anything in our way from expanding and accreting gross margins. We are expecting, as we continue to accelerate our growth in Q3 and beyond, we will continue to expect, and you will see margin accretion in a meaningful way.

Speaker 1

Okay. Just last question, regarding the new facility that you acquired, which I think is sort of a bullish statement that you think potentially there's a lot more to grow here. When you talk about expanding capacity by 30% potentially, and you're only going to have a modest level of CapEx behind that, what's a realistic timeframe for you to be able to achieve that level of capacity expansion? Just so we could also think of how much you're going to be allocating in terms of your cash flow towards that capacity expansion. Thanks.

Speaker 3

Thank you, Gary. You're obviously referring to the real estate that we announced that we purchased in July, a five-acre piece of land. There's a building on it. In the near term, our focus is scalability. This building is going to provide us the ability to enhance supply chain, cold storage, testing, distribution. It was a reasonable purchase price, and the capacity expansion is really because we're looking at the future here. We are operating in a market that continues to grow rapidly. Ig utilization is not slowing down. The demand for our products in that is growing at a very rapid clip. You see, with yield enhancement, we're reporting that we are experiencing the 20%+ increase in bulk Ig output as well as finished goods. We need a place to keep it while it's finishing its testing and a place to distribute it from.

We're looking at this as it's really going to help support and sustain the durable growth outlook that we're looking for. With regard to capacity expansion, we figured someone would ask this question. We're thinking about the future, and the press release today talks about some encouraging developments with SG-001. That's our follow-on high-titer hyperimmune product with high levels of neutralizing antibodies targeting Streptococcus pneumoniae. The data is very encouraging there, and we want folks to understand that our board and the management here is looking at building a highly durable cash-generating business into the future. I think everyone understands this, at least those that are following ADMA Biologics. We've got multiple buildings on our existing campus, and I'm speaking to you today from an office in the building that houses our GMP manufacturing area.

The best thing to do is to get rid of all the offices at some point in time and move those offices and turn what is office space today into GMP production space. We don't have any plans to start it today, Gary. From a CapEx perspective, we're not looking at expanding capacity today, but what this infrastructure enhancement has done by acquiring this building adjacent to our campus here is allowing us to plan for the future, allowing us to really think about, we don't want to take away capacity from one of our existing products if and when SG-001 comes on board. If ASCENIV continues to outperform like it has been our current capacity, we now can look at investors and other constituents straight in the face and say, we've got the ability to really expand here in a meaningful way. We've given top-line guidance of $1.1 billion.

That doesn't bake in anything from this. This is going to help us to support a multi-billion dollar revenue entity.

Speaker 2

Yeah, Gary, just to further Adam's point. We mentioned a $1.1 billion top line prior to 2030. We do not need this building or additional capacity to achieve that $1.1 billion, and I'll call it a milestone because it's a milestone. What this additional capacity does is it turns that milestone certainly not into a ceiling. This is part of our journey. This is part of what Adam is talking about, our future growth. I just want to reiterate that that $1.1 billion top line is not dependent on this additional capacity. This additional capacity will continue to help and grow our future.

Speaker 1

Okay. Thanks for all that color, guys. Appreciate it.

Speaker 3

Thank you, Gary.

Speaker 4

This will conclude our question-and-answer portion of the call. I'd like to turn it back over to Adam for additional closing remarks.

Speaker 3

Thanks again, everyone. Thanks for dialing into our call. Again, really excited about the performance. I want to take my hat off to the ADMA Biologics team. Yield enhancement is a tremendous achievement, and now we've got more product to treat more patients. Thank you to everybody. Donate plasma, and we look forward to speaking to you next quarter.

Speaker 1

Take care.

Speaker 4

Ladies and gentlemen, this does conclude the conference call for today. We appreciate your participation, and you may now disconnect.